Inclusion: Adults (18 years and older) with gout who have had gout flare(s)

Strata: None

Exclusion: people with calcium pyrophosphate crystal deposition, including pseudogout

Follow-up care strategies, including:

Specific frequencies and durations

Led by specific healthcare professionals

Settings (community versus secondary/hospital-based care)

Patient- tailored

Within-type comparisons (e.g. community versus secondary/hospital-based care)

Compared to each other

Standard/usual care

Control (no follow-up)

All outcomes are considered equally important for decision making and therefore have all been rated as critical:

• health-related quality of life (e.g. as described by SF-36, Gout Assessment Questionnaire (GAQ) and the Gout Impact Scale (GIS) or other validated gout-specific HRQoL measures
• frequency of flares
• patient global assessment of treatment success (response to treatment) (e.g. Likert scales, visual analogue scales (VAS), numerical ratings scales (NRS))
• proportion of people with gout using ULT
• patient awareness of their condition/treatment
• serum urate levels
• admissions (hospital and A&E/urgent care)
• GP visits

Timepoints: short-term (less than three months), medium-term (three to 12 months) and long-term (more than 12 months) duration.

RCT

Systematic reviews of RCTs

If insufficient RCT evidence is available (no or little evidence for interventions/comparisons), search for non-randomised studies (prospective and retrospective cohort studies will be considered if they adjust for key confounders:

• Age
• Gender

Published NMAs will be considered for inclusion.